QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
QQQ   397.83 (+3.01%)
AAPL   171.18 (+3.54%)
MSFT   334.92 (+2.68%)
FB   322.81 (+1.55%)
GOOGL   2,945.39 (+2.87%)
AMZN   3,523.29 (+2.80%)
TSLA   1,051.75 (+4.24%)
NVDA   324.27 (+7.96%)
BABA   125.54 (+1.57%)
NIO   33.12 (+2.41%)
CGC   10.64 (+4.83%)
AMD   144.85 (+4.16%)
GE   97.55 (+1.60%)
MU   85.83 (+4.10%)
T   23.08 (-0.86%)
F   19.96 (+3.85%)
DIS   150.81 (+0.29%)
PFE   51.72 (+0.47%)
AMC   31.04 (+7.82%)
ACB   6.38 (+6.87%)
BA   208.83 (+1.43%)
OTCMKTS:PTIX

Protagenic Therapeutics Stock Forecast, Price & News

$1.68
+0.03 (+1.82%)
(As of 12/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.61
$1.71
50-Day Range
$1.63
$2.32
52-Week Range
$1.46
$7.00
Volume
74,142 shs
Average Volume
1.72 million shs
Market Capitalization
$28.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.36
30 days | 90 days | 365 days | Advanced Chart
Receive PTIX News and Ratings via Email

Sign-up to receive the latest news and ratings for Protagenic Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Protagenic Therapeutics logo

About Protagenic Therapeutics

Protagenic Therapeutics, Inc. is a biotechnology company, which engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Headlines

Reviewing Protagenic Therapeutics (PTIX) & Its Peers
November 26, 2021 |  americanbankingnews.com
Comparing Protagenic Therapeutics (PTIX) and Its Rivals
November 24, 2021 |  americanbankingnews.com
Critical Survey: Protagenic Therapeutics (PTIX) versus Its Peers
November 19, 2021 |  americanbankingnews.com
Protagenic Therapeutics Inc.
June 13, 2021 |  barrons.com
See More Headlines

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:PTIX
Employees
1
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$0.61 per share

Profitability

Net Income
$-2.55 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
9,326,000
Market Cap
$28.49 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/16/2021
Today
12/07/2021
Fiscal Year End
12/31/2021

MarketRank

Overall MarketRank

1.91 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Protagenic Therapeutics (OTCMKTS:PTIX) Frequently Asked Questions

Is Protagenic Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Protagenic Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Protagenic Therapeutics stock.
View analyst ratings for Protagenic Therapeutics
or view top-rated stocks.

How has Protagenic Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Protagenic Therapeutics' stock was trading at $1.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PTIX shares have decreased by 1.2% and is now trading at $1.68.
View which stocks have been most impacted by COVID-19
.

How were Protagenic Therapeutics' earnings last quarter?

Protagenic Therapeutics, Inc. (OTCMKTS:PTIX) announced its earnings results on Tuesday, November, 16th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.03.
View Protagenic Therapeutics' earnings history
.

What price target have analysts set for PTIX?

1 brokers have issued 12 month price objectives for Protagenic Therapeutics' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Protagenic Therapeutics' stock price to reach $4.00 in the next year. This suggests a possible upside of 138.1% from the stock's current price.
View analysts' price targets for Protagenic Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Protagenic Therapeutics' key executives?

Protagenic Therapeutics' management team includes the following people:
  • Andrew Slee, Chief Operating Officer
  • Alexander K. Arrow, Chief Financial Officer & Secretary
  • Robert Benjamin Stein, Director & Chief Medical Officer

What other stocks do shareholders of Protagenic Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Protagenic Therapeutics investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), (PCSA), Acasti Pharma (ACST), Akero Therapeutics (AKRO), Athersys (ATHX), AVEO Pharmaceuticals (AVEO), CymaBay Therapeutics (CBAY), Cerecor (CERC) and Cumberland Pharmaceuticals (CPIX).

What is Protagenic Therapeutics' stock symbol?

Protagenic Therapeutics trades on the OTCMKTS under the ticker symbol "PTIX."

Who are Protagenic Therapeutics' major shareholders?

Protagenic Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Oracle Investment Management Inc. (2.98%), Geode Capital Management LLC (0.62%), Morgan Stanley (0.35%) and Citadel Advisors LLC (0.23%).
View institutional ownership trends for Protagenic Therapeutics
.

Which major investors are buying Protagenic Therapeutics stock?

PTIX stock was purchased by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., Morgan Stanley, Geode Capital Management LLC, and Citadel Advisors LLC.
View insider buying and selling activity for Protagenic Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Protagenic Therapeutics?

Shares of PTIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Protagenic Therapeutics' stock price today?

One share of PTIX stock can currently be purchased for approximately $1.68.

How much money does Protagenic Therapeutics make?

Protagenic Therapeutics has a market capitalization of $28.49 million. The biotechnology company earns $-2.55 million in net income (profit) each year or ($0.32) on an earnings per share basis.

How many employees does Protagenic Therapeutics have?

Protagenic Therapeutics employs 1 workers across the globe.

What is Protagenic Therapeutics' official website?

The official website for Protagenic Therapeutics is www.protagenic.com.

Where are Protagenic Therapeutics' headquarters?

Protagenic Therapeutics is headquartered at 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010.

How can I contact Protagenic Therapeutics?

Protagenic Therapeutics' mailing address is 149 FIFTH AVENUE SUITE 500, NEW YORK NY, 10010. The biotechnology company can be reached via phone at (212) 994-8200, via email at [email protected], or via fax at 603-761-6223.


This page was last updated on 12/7/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.